Pulse Biosciences, Inc. (PLSE)
| Market Cap | 3.92B +255.5% |
| Revenue (ttm) | 1.49M +1,637.2% |
| Net Income | -83.72M |
| EPS | -1.21 |
| Shares Out | 73.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 428,499 |
| Open | 56.87 |
| Previous Close | 53.07 |
| Day's Range | 50.31 - 56.87 |
| 52-Week Range | 12.56 - 58.90 |
| Beta | 1.64 |
| Analysts | Strong Buy |
| Price Target | 66.67 (+25.11%) |
| Earnings Date | Nov 5, 2026 |
About PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled conso... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for PLSE stock is "Strong Buy." The 12-month stock price target is $66.67, which is an increase of 25.11% from the latest price.
News
Pulse Biosciences price target raised to $74 from $58 at Canaccord
Canaccord raised the firm’s price target on Pulse Biosciences (PLSE) to $74 from $58 and keeps a Buy rating on the shares. The firm said Q3/26 revenue was in line,…
Pulse Biosciences price target raised to $65 from $55 at Mizuho
Mizuho raised the firm’s price target on Pulse Biosciences (PLSE) to $65 from $55 and keeps an Outperform rating on the shares.
Pulse Biosciences announces interim results from PRECISE-BTN
Pulse Biosciences (PLSE) announced interim six-month results from PRECISE-BTN, a prospective, multicenter U.S. study evaluating the nPulse Vybrance Percutaneous Electrode System. The results were pres...
Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technolo...
Pulse Biosciences reports Q3 EPS (32c), consensus (29c)
Reports Q3 revenue $395,000, consensus $521,670. Cash, cash equivalents, and marketable securities totaled $189.2M as of September 30, 2026, compared to $101.6M as of June 30, 2026. “Pulse Biosciences...
Pulse Biosciences Earnings Call Transcript: Q3 2026
NANOPULSE-AF enrollment finished three months early, and Q3 ended with $189.2M in cash and marketable securities. Final pivotal data are expected in Q3 2027 as spending and launch-readiness investment increase.
Pulse Biosciences Quarterly report: Q3 2026
Pulse Biosciences has published its Q3 2026 quarterly earnings report on November 5, 2026.
Pulse Biosciences Earnings release: Q3 2026
Pulse Biosciences released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technolo...
Pulse Biosciences to Present at Stifel 2026 Healthcare Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technolo...
Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technolo...
Pulse Biosciences announces partnership with Clayman Thyroid Center
Pulse Biosciences (PLSE) announced a partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The partnership covers both the commercial use of the nPulse…
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technolo...
Pulse Biosciences price target raised to $60 from $35 at Oppenheimer
Oppenheimer raised the firm’s price target on Pulse Biosciences (PLSE) to $60 from $35 and keeps an Outperform rating on the shares after accompanying Pulse management on a West Coast…
Pulse Biosciences price target raised to $55 from $45 at Mizuho
Mizuho raised the firm’s price target on Pulse Biosciences (PLSE) to $55 from $45 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical devices…
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technolo...
Pulse Biosciences' nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technolo...
Pulse Biosciences announces NANOPULSE-AF study met enrollment target
Pulse Biosciences (PLSE) announced that its NANOPULSE-AF Study has reached its enrollment target of 164 evaluable patients across 15 clinical sites. “The enrollment pace reflects the enthusiasm we saw...
Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announ...
Pulse Biosciences price target raised to $58 from $43 at Canaccord
Canaccord raised the firm’s price target on Pulse Biosciences (PLSE) to $58 from $43 and keeps a Buy rating on the shares. The firm met with management where they discussed…
Pulse Biosciences management to meet with Oppenheimer
Meeting to be held in San Francisco on October 7-8 hosted by Oppenheimer.
Pulse Biosciences management to meet virtually with Freedom Capital
Virtual Meeting to be held on September 29 hosted by Freedom Capital.
Pulse Biosciences initiated with a Buy at BTIG
BTIG initiated coverage of Pulse Biosciences (PLSE) with a Buy rating and $70 price target The company has developed a nanosecond pulsed field ablation technology that operates meaningfully faster tha...
Pulse Biosciences falls -10.6%
Pulse Biosciences (PLSE) is down -10.6%, or -$5.85 to $49.35.
Pulse Biosciences falls -6.2%
Pulse Biosciences (PLSE) is down -6.2%, or -$3.42 to $51.78.